COPENHAGEN, Feb 23 (Reuters) - Novo Nordisk's next-generation obesity drug CagriSema underperformed Eli Lilly's Zepbound in a head-to-head trial, the Danish drugmaker said on Monday, as it suffered a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results